预兆将Vaxcyte的股份提高4.6%,表明对生物技术公司疫苗开发的信心。 Vanguard boosts Vaxcyte shares by 4.6%, signaling confidence in the biotech firm's vaccine development.

前卫公司在Vaxcyte(一家开发蛋白质疫苗的生物技术公司)的持有量增加了4.6%,达到11 961 687股,价值9.79亿美元。 Vanguard increased its holdings in Vaxcyte, a biotech firm developing protein vaccines, by 4.6% to 11,961,687 shares, valued at $979 million. 与此同时,Sei Investments通过出售17 535股减少了股份,现在拥有161 682股。 Meanwhile, Sei Investments reduced its stake by selling 17,535 shares, now owning 161,682 shares. Vaxcyte的铅疫苗VAX-24,目标为肺炎球菌疾病,该公司还研制抗生素抗药性疫苗A类链球菌、脑膜炎和Shigella疫苗。 Vaxcyte's lead vaccine, VAX-24, targets pneumococcal disease, and the company also develops vaccines for antibiotic resistance, Group A Streptococcus, periodontitis, and Shigella. Vaxcyte的股票市场上限为89.4亿美元,并获得分析师的“Buy”评级,价格目标为147.50美元。 Vaxcyte's stock has a market cap of $8.94 billion and received a "Buy" rating from analysts with a price target of $147.50.